Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig 1 Timing and cumulative rate of venous thromboembolism among patients in Ontario treated with orchiectomy for testicular cancer during 2000–2010 (n = 2648). Highlights •A population-based assessment of thromboembolic risk in testes cancer patients was performed in Ontario, Canada.
Introduction The advent of cisplatin-based chemotherapy transformed testicular cancer into the most curable metastatic solid malignancy, with 5-year survival rates exceeding 95% [1x[1]Trama, A., Foschi, R., Larranaga, N., Sant, M., Fuentes-Raspall, R., Serraino, D. et al. Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: results from the EUROCARE-5 study. Eur J Cancer. 2015; 51: 2206–2216 Google ScholarSee all References][1].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.